{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:45Z","timestamp":1760122665713},"reference-count":40,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.017","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T02:16:53Z","timestamp":1492136213000},"page":"2801-2810","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vaccination with the polymorphic membrane protein A reduces  Chlamydia muridarum  induced genital tract pathology"],"prefix":"10.1016","volume":"35","author":[{"given":"Tina","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Stallmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Waldhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"R\u00f6mmler-Dreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes H.","family":"Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Miethke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.017_b0005","unstructured":"Annual epidemiological report 2014 \u2013 sexually transmitted infections, including HIV and blood-borne viruses. Stockholm: ECDC: Euopean centre for disease prevention and control; 2015."},{"key":"10.1016\/j.vaccine.2017.04.017_b0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CMR.00035-15","article-title":"Human and pathogen factors associated with Chlamydia trachomatis-related infertility in women","volume":"28","author":"Menon","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.04.017_b0015","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.vaccine.2013.01.024","article-title":"Chlamydia trachomatis control requires a vaccine","volume":"31","author":"Brunham","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/OLQ.0b013e31815e41a3","article-title":"The arrested immunity hypothesis and the epidemiology of chlamydia control","volume":"35","author":"Brunham","year":"2008","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.04.017_b0025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.vaccine.2013.10.016","article-title":"Towards a safe and effective chlamydial vaccine: lessons from the eye","volume":"32","author":"Mabey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0030","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.4049\/jimmunol.179.6.4027","article-title":"Plasmid-deficient chlamydia muridarum fail to induce immune pathology and protect against oviduct disease","volume":"179","author":"O'Connell","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0035","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/IAI.00169-12","article-title":"The recall response induced by genital challenge with chlamydia muridarum protects the oviduct from pathology but not from reinfection","volume":"80","author":"Riley","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.017_b0040","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.20111266","article-title":"A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates","volume":"208","author":"Kari","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.04.017_b0045","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.vaccine.2013.08.020","article-title":"Development status and future prospects for a vaccine against chlamydia trachomatis infection","volume":"32","author":"Hafner","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0050","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.4049\/jimmunol.1303392","article-title":"Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum","volume":"192","author":"Tifrea","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.micinf.2013.11.009","article-title":"A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge","volume":"16","author":"Cheng","year":"2014","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2017.04.017_b0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mbo3.186","article-title":"All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function","volume":"3","author":"Becker","year":"2014","journal-title":"MicrobiologyOpen"},{"key":"10.1016\/j.vaccine.2017.04.017_b0065","series-title":"Intracellular Pathogens I: Chlamydiales","article-title":"Chlamydial adhesion and adhesins","author":"Hegemann","year":"2012"},{"key":"10.1016\/j.vaccine.2017.04.017_b0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/omi.1.1999.4.187","article-title":"Computational analysis of the polymorphic membrane protein superfamily of chlamydia trachomatis and chlamydia pneumoniae","volume":"4","author":"Grimwood","year":"1999","journal-title":"MicrobComp Genomics"},{"key":"10.1016\/j.vaccine.2017.04.017_b0075","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1365-2958.2010.07386.x","article-title":"Members of the Pmp protein family of chlamydia pneumoniae mediate adhesion to human cells via short repetitive peptide motifs","volume":"78","author":"Molleken","year":"2010","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0080","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.4049\/jimmunol.180.4.2459","article-title":"Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia","volume":"180","author":"Karunakaran","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0085","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1016\/j.vaccine.2014.06.002","article-title":"Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice","volume":"32","author":"Yu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/JB.188.1.275-286.2006","article-title":"Polymorphisms in the nine polymorphic membrane proteins of Chlamydia trachomatis across all serovars: evidence for serovar Da recombination and correlation with tissue tropism","volume":"188","author":"Gomes","year":"2006","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1189\/jlb.0113014","article-title":"Ly6 family proteins in neutrophil biology","volume":"94","author":"Lee","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0100","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/IAI.05022-11","article-title":"Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection","volume":"79","author":"Murthy","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.017_b0105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1128\/IAI.01668-13","article-title":"Signaling via tumor necrosis factor receptor 1 but not toll-like receptor 2 contributes significantly to hydrosalpinx development following chlamydia muridarum infection","volume":"82","author":"Dong","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.017_b0110","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/infdis\/jiu839","article-title":"Tumor necrosis factor (TNF) receptor superfamily member 1b on CD8+ T cells and TNF receptor superfamily member 1a on non-CD8+ T Cells contribute significantly to upper genital tract pathology following chlamydial infection","volume":"211","author":"Manam","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.017_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1574-695X.2008.00509.x","article-title":"Considerations on chlamydia trachomatis disease expression","volume":"55","author":"Brunham","year":"2009","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2334-12-187","article-title":"Timing of progression from chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study","volume":"12","author":"Herzog","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.017_b0125","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/aje\/kws583","article-title":"Risk of pelvic inflammatory disease following chlamydia trachomatis infection: analysis of prospective studies with a multistate model","volume":"178","author":"Price","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1462-5822.2009.01389.x","article-title":"Variable expression of surface-exposed polymorphic membrane proteins in in vitro-grown chlamydia trachomatis","volume":"12","author":"Tan","year":"2010","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0135","doi-asserted-by":"crossref","first-page":"e0131695","DOI":"10.1371\/journal.pone.0131695","article-title":"Bioinformatic analysis of chlamydia trachomatis polymorphic membrane proteins PmpE, PmpF, PmpG and PmpH as potential vaccine antigens","volume":"10","author":"Nunes","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.017_b0140","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.vaccine.2015.02.055","article-title":"Outer membrane proteins preferentially load MHC class II peptides: implications for a chlamydia trachomatis T cell vaccine","volume":"33","author":"Karunakaran","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0145","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/IAI.06338-11","article-title":"Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice","volume":"80","author":"Yu","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.017_b0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jri.2014.01.002","article-title":"Frequency of chlamydia trachomatis-specific T cell interferon-gamma and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females","volume":"103","author":"Barral","year":"2014","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1189\/jlb.0210083","article-title":"Increased inflammation and impaired resistance to chlamydophila pneumoniae infection in Dusp1-\/- mice: critical role of IL-6","volume":"88","author":"Rodriguez","year":"2010","journal-title":"J Leukoc Biol"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2017.04.017_b0160","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0002-9394(67)94155-4","article-title":"Trachoma vaccine studies in monkeys","volume":"63","author":"Wang","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.vaccine.2017.04.017_b0165","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4269\/ajtmh.1969.18.723","article-title":"Studies on trachoma. VI. microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels","volume":"18","author":"Nichols","year":"1969","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.04.017_b0170","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4269\/ajtmh.1966.15.639","article-title":"Studies on trachoma. V. clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia","volume":"15","author":"Nichols","year":"1966","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.04.017_b0175","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1073\/pnas.1101756108","article-title":"Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of chlamydia trachomatis vaccines","volume":"108","author":"Finco","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.04.017_b0180","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2007.02.010","article-title":"Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital chlamydia muridarum infection","volume":"25","author":"Cong","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0185","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/j.vaccine.2009.02.095","article-title":"A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice","volume":"27","author":"Wang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0190","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2013.09.036","article-title":"A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.017_b0195","first-page":"348","article-title":"A mucosal vaccine against chlamydia trachomatis generates two waves of protective memory T cells","author":"Stary","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.017_b0200","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/IAI.00673-15","article-title":"In vivo and ex vivo imaging reveals a long-lasting chlamydial infection in the mouse gastrointestinal tract following genital tract inoculation","volume":"83","author":"Zhang","year":"2015","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T08:39:10Z","timestamp":1529915950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17304814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17304814"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}